The effect of bezafibrate slow release (400 mg/day) and of simvastatin (20 mg/day) on Lp(a) and fibrinogen plasma levels were evaluated in a placebo-controlled double blind study in 75 patients with type IIa and IIb hyperlipoproteinemia with elevated levels of Lp(a) and fibrinogen. 61 patients completed the study. After 6 months of treatment placebo did not influence any of those parameters; simvastatin and bezafibrate significantly reduced (p <0.01) plasma cholesterol (by 20 and 15%), LDL cholesterol (by 30 and 20%), as well as apo B (by 16 and 19%). Bezafibrate also significantly (p <0.01) reduced plasma triglycerides (32%) and increased HDL cholesterol and A-I levels (by 13 and 14% respectively). In addition to these effects on plasma lipid profile bezafibrate significantly decreased elevated plasma Lp(a) levels (from 47 to 41 U/dl, p <0.05) and fibrinogen levels (by 14%, p <0.01). It is concluded that bezafibrate besides the effect on plasma lipoprotein can also lower elevated Lp(a) and fibrinogen plasma levels.
|Translated title of the contribution||Effects of bezafibrate on Lp(a) plasma levels in patients with IIa and IIb hyperlipoproteinemia|
|Number of pages||7|
|Journal||Giornale della Arteriosclerosi|
|Publication status||Published - 1994|
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine